G. Bencze

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Relationship of Systemic Lupus Erythematosus to Rheumatoid Arthritis, Discoid Lupus Erythematosus, and Sjögren's Syndrome

G. Bencze, L Lakatos · Annals of the Rheumatic Diseases · 1963 · 25 citations

Medicine, Immunology, Internal Medicine +15

Two Types of Lupus Erythematosus Cell Factor, Shown by Induced L.E. Cell Phenomenon in Man

G. Bencze, Judit Kovács, J. Cserhati · BMJ · 1959 · 18 citations · Full text

Life Sciences, Immunology, Pathology +10